Holen Sie sich die Stockscreener-App
8.215
1.86%
0.155
Schlusskurs vom Vortag:
$8.06
Offen:
$8.08
24-Stunden-Volumen:
348.31K
Relative Volume:
0.21
Marktkapitalisierung:
$2.57B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-12.07
EPS:
-0.6805
Netto-Cashflow:
$229.23M
1W Leistung:
+3.79%
1M Leistung:
+0.98%
6M Leistung:
-5.96%
1J Leistung:
+10.34%
1-Tages-Spanne:
$8.08
$8.23
1-Wochen-Bereich:
$7.83
$8.23
52-Wochen-Spanne:
$6.50
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Vergleichen Sie AMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
8.215 | 2.53B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
151.98 | 67.73B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.31 | 45.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.735 | 44.38B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.50 | 18.97B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
299.77 | 13.73B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
What institutional investors are buying Amneal Pharmaceuticals Inc. stockExceptional earning trajectories - jammulinksnews.com
How does Amneal Pharmaceuticals Inc. generate profit in a changing economyUnlock high-yield investment opportunities - jammulinksnews.com
What are the technical indicators suggesting about Amneal Pharmaceuticals Inc.Capitalize on emerging investment opportunities - jammulinksnews.com
How many analysts rate Amneal Pharmaceuticals Inc. as a “Buy”Achieve rapid financial growth with expert picks - jammulinksnews.com
Why Amneal Pharmaceuticals Inc. stock attracts strong analyst attentionCapital Safe Smart Trades - metal.it
How Amneal Pharmaceuticals Inc. stock performs during market volatilityFree Stock Selection with 300% Return - metal.it
Amneal Pharmaceuticals Inc. Stock Analysis and ForecastMassive portfolio appreciation - PrintWeekIndia
What drives Amneal Pharmaceuticals Inc. stock priceFree Investment Community - PrintWeekIndia
Amneal Pharmaceuticals Prices $600M Senior Notes Offering - MSN
Is Amneal Pharmaceuticals Inc. a good long term investmentPowerful profit generation - PrintWeekIndia
Amneal Pharmaceuticals prices $600 million in senior secured notes, increases term loan - Investing.com Nigeria
What analysts say about Amneal Pharmaceuticals Inc. stockFree Investment Community - Autocar Professional
Amneal Pharmaceuticals prices $600 million in senior secured notes, increases term loan By Investing.com - Investing.com South Africa
Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S - simplywall.st
Amneal Announces Proposed Refinancing of Existing Credit - GlobeNewswire
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results - The Globe and Mail
Amneal seeks to borrow $1.8 billion in new term loans, offers notes - Investing.com Canada
Amneal reports 3% revenue growth in Q2, advances deleveraging By Investing.com - Investing.com South Africa
Amneal (AMRX) targets $2.55B debt refinancing via loans & notes | AMRX SEC FilingForm 8-K - Stock Titan
Amneal Pharmaceuticals Reports Preliminary Q2 2025 Financial Results Indicating Growth and Deleveraging Efforts - Nasdaq
Silicon Valley - FinancialContent
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada - The Manila Times
Thérapeutique Knight annonce le dépôt d’une nouvelle soumission réglementaire pour CREXONT® (carbidopa et lévodopa) au Canada en capsules à libération prolongée - GlobeNewswire Inc.
Parkinson's Disease Pipeline 2025: MOA and ROA Insights, - openPR.com
Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension - MSN
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.22%
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):